Testing Con	ditions	Routine QC Recommendations (see Tables 4A-1 and 5A-1 for acceptable QC ranges)			
Medium:	Disk diffusion: MHA Broth dilution: CAMHB; iron-depleted CAMHB for cefiderocol (see Appendix I) ¹ Agar dilution: MHA	Escherichia coli ATCC®a 25922 (for chloramphenicol, minocycline, and trimethoprim-sulfamethoxazole) Pseudomonas aeruginosa ATCC® 27853			
Inoculum:	Broth culture method or colony suspension, equivalent to a 0.5 McFarland standard	Refer to Tables 4A-2 and 5A-2 to select strains for routine QC of B-lactam combination agents.			
Incubation:	35°C \pm 2°C; ambient air; 20-24 hours, all methods	When a commercial test system is used for susceptibility testing, refer to the manufacturer's instructions for QC test recommendations and QC ranges.			

Table 2B-4. Zone Diameter and MIC Breakpoints for Stenotrophomonas maltophilia

General Comment

(1) Refer to Table 1F for antimicrobial agents that should be considered for testing and reporting by microbiology laboratories.

(2) For disk diffusion, test a maximum of 12 disks on a 150-mm plate and no more than 6 disks on a 100-mm plate; disks should be placed no less than 24 mm apart, center to center (see M02,² Subchapter 3.6). Each zone diameter should be clearly measurable; overlapping zones prevent accurate measurement. Measure the diameter of the zones of complete inhibition (as judged by the unaided eye), including the diameter of the disk (see the M02 Disk Diffusion Reading Guide³). Hold the Petri plate a few inches above a black background illuminated with reflected light. The zone margin should be considered the area showing no obvious, visible growth that can be detected with the unaided eye. Ignore faint growth of tiny colonies that can be detected only with a magnifying lens at the edge of the zone of inhibited growth. With trimethoprim and the sulfonamides, antagonists in the medium may allow some slight growth; therefore, disregard slight growth (20% or less of the lawn of growth) and measure the more obvious margin to determine the zone diameter.

NOTE: Information in black boldface type is new or modified since the previous edition.

M100-Ed33

Table 2B-4. Stenotrophomonas maltophilia (Continued)

Table 2B-4. Stenotrophomonas maltophilia (Continued)										
Antimicrobial	Disk	Interpretive Categories and Zone Diameter Breakpoints, nearest whole mm		Interpretive Categories and MIC Breakpoints, ug/mL						
Antimicrobial	Content	S		R	S		R	Comments		
B-LACTAM COMBINATION AGENTS										
Ticarcillin-clavulanate*	-	-	-		≤16/2	32/2-64/2	<u>≥128/2</u>			
CEPHEMS (PARENTERAL) (Including cephalosporins I, II, III, and IV. Please refer to Glossary I.)										
Ceftazidime	-	-	-	-	≤8	16	≥32			
Cefiderocol	30 µg	≥15	-	-	≤1	-	-	 (3) Breakpoints are based on a dosage regimen of 2 g every 8 h administered over 3 h. Breakpoints are based on PK/PD properties, MIC distributions, and limited clinical data. (4) The accuracy and reproducibility of cefiderocol testing results by disk diffusion and broth microdilution are markedly affected by iron concentration and inoculum preparation and may vary by disk and media manufacturer. Depending on the type of variance observed, false-resistant or false-susceptible results may occur. Testing subsequent isolates is encouraged. Discussion with prescribers and antimicrobial stewardship members regarding the potential for inaccuracies is recommended. 		
TETRACYCLINES		1			1	·	·			
Minocycline	30 µg	≥19	15-18	≤14	≤4	8	≥16			
FLUOROQUINOLONES										
Levofloxacin	5 µg	≥17	14-16	≤13	≤2	4	≥8	(5) <i>Rx</i> : Levofloxacin should not be used alone for antimicrobial therapy.		
FOLATE PATHWAY ANTAGONISTS										
Trimethoprim- sulfamethoxazole	1.25/23.75 μg	≥16	11-15	≤10	≤2/38	-	≥4/76			
PHENICOLS		1								
Chloramphenicol*	-	-	-	-	≤8	16	≥32	(6) Not routinely reported on organisms isolated from the urinary tract.		
Allele and the second ATCCO And	·		1 - 1 1 4 2	C		1.4 · · · · · · · · · · · · · · · · · · ·		and the state of t		

Abbreviations: ATCC[®], American Type Culture Collection; CAMHB, cation-adjusted Mueller-Hinton broth; I, intermediate; MHA, Mueller-Hinton agar; MIC, minimal inhibitory concentration; QC, quality control; PK/PD, pharmacokinetic/pharmacodynamic; R, resistant; S, susceptible.

Symbol: *, designation for "Other" agents that are not included in Tables 1 but have established clinical breakpoints.

Table 2B-4. Stenotrophomonas maltophilia (Continued)

Footnote

a. ATCC[®] is a registered trademark of the American Type Culture Collection.

References for Table 2B-4

1

3

Badrīva Al Adawi ant is protected by copyright. CLSI order #Ord-8360ª[7];19]bww/loandeb.domo2061/28923.tandards Institute.

All rights reserved

- Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. *Diagn Microbiol Infect Dis*. 2019;94(4):321-325.
- ² CLSI. *Performance Standards for Antimicrobial Disk Susceptibility Tests*. 13th ed. CLSI standard M02. Clinical and Laboratory Standards Institute; 2018.
- CLSI. M02 Disk Diffusion Reading Guide. 1st ed. CLSI quick guide M02QG. Clinical and Laboratory Standards Institute; 2018.